Gremubamab
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02255760)
Timeline
Indications
Mechanism of action
- Pseudomonas aeruginosaANTAGONIST
Pseudomonas aeruginosa antagonist
- PslBINDING AGENT
Psl bindi
- Low calcium response locus protein VINHIBITOR
Low calcium response locus protein V inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298031 ↗
Also known as
- medi3902
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02696902 | Phase 2 | Mar 25, 2016 | MedImmune |
| NCT02255760 | Phase 1 | Sep 1, 2014 | MedImmune, MRA Clinical Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 2 | 2 | 2 | 2014 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1